本文来源:时代财经 作者:杜苏敏将肿瘤药业务板块分拆上市,老牌药企先声药业(02096.HK)“仿转创”战略进入下半场。近日,先声药业发布公告称,本公司建议分拆附属公司先声再明的H股在港交所主板独立上市。港交所已确认本公司可进行建议分拆。同日,先声再明向港交所提交上市申请,联席保荐人为中金公司和摩根士丹利。先声药业强调,于本公告日期,本公司间接持有先声再明已发行股本总额约83.10%。按照计划,待...
Source Link本文来源:时代财经 作者:杜苏敏将肿瘤药业务板块分拆上市,老牌药企先声药业(02096.HK)“仿转创”战略进入下半场。近日,先声药业发布公告称,本公司建议分拆附属公司先声再明的H股在港交所主板独立上市。港交所已确认本公司可进行建议分拆。同日,先声再明向港交所提交上市申请,联席保荐人为中金公司和摩根士丹利。先声药业强调,于本公告日期,本公司间接持有先声再明已发行股本总额约83.10%。按照计划,待...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.